Magnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approach

Abstract

ObjectivesTo evaluate the short-term 24 h urinary excretion of platinum, arsenic, selenium, magnesium and zinc in patients with lung cancer and with cancer other than lungs treated with cisplatin or/and carboplatin from Antofagasta, Chile.DesignUrine measurements of Pt and Se were made by inductively coupled plasma optical emission spectrometry, As by hydride-generation atomic absorption spectrometry and Mg and Zn by means of flame furnace atomic absorption spectrometry.SettingAll samples were provided by the Oncological Centre of Antofagasta Regional Hospital (Region of Antofagasta, Chile).ParticipantsNinety 24-h urine samples from cancer patients after the infusion of Pt-base drugs and 10 24-h urine samples from cancer patients not treated with metal-base drugs.Main outcome measuresConcentrations of Pt, Se, As, Zn and Mg coming from 24-h urine samples.ResultsPt excreted was not significantly different between patients with lung and other cancers treated with cisplatin. The excretion of Mg, Zn and Se was greater than As. Then, Pt favours the excretion of essential elements. For lung and other types of cancers treated with drugs without Pt, excretion of Mg, Zn and Se was also greater than that of As, suggesting antagonism Mg-Zn-Se–anti-cancer drug relationship.ConclusionsThe amounts of Mg, Zn and Se excreted were greater than for As either with or without Pt-containing drugs, suggesting antagonist Mg-Zn-Se–anti-cancer drug relationships. The excretion of As, Mg, Zn and Se is induced by Pt. Knowledge obtained can contribute to understanding the arsenic cancer mechanism and the As-Mg-Zn-Se-Pt inter-element association for lung cancer and other types of cancer.

Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer

“…The analysis in the top z-score of 790 analyses for carboplatin in depth 3 of the master regulators was in diffuse large B-cell lymphoma (DLBCL) (as of 2022) (Figure 1a). In this analysis, N-(furan-2-ylmethyl)-8-(4-methylsulfonylphenyl)- [1,2,4]triazolo [4,3-c]pyrimidin-5-amine (EED226) (5 µM, 24 h), a potent and selective inhibitor of polycomb repressive complex 2 (PRC2) that directly binds to the histone H3 lysine 27 binding pocket of embryonic ectoderm development (EED), a subunit of PRC2, was treated to DLBCL [42]. Bioprofiler analysis on carboplatin identified the relationship between carboplatin and anaplastic lymphoma kinase receptor tyrosine kinase (ALK) mutation-negative CD274 positive non-small cell lung cancer, ALK mutation negative epidermal growth factor receptor (EGFR) sensitizing mutation negative non-squamous non-small cell lung cancer, CD274 low expression positive non-squamous non-small cell lung cancer, EGFR mutation-negative CD274 positive non-small cell lung cancer, or locally advanced non-squamous non-small cell lung cancer (Figure 1b,c).…”

“…Metallodrugs, including platinum drugs and arsenic trioxide, are widely used as cancer therapeutics [1][2][3][4][5]. Platinum drugs, such as cisplatin and carboplatin, are commonly used for the treatment of a variety of cancers, including bladder, head and neck, lung, gastrointestinal, ovarian, and testicular cancer [6,7].…”

Molecular Networks of Platinum Drugs and Arsenic Trioxide and Its Interaction With microRNAs in Cancer

“…Metallodrugs, including platinum drugs and arsenic, are widely used as cancer therapeutics [1][2][3][4][5]. Platinum drugs, such as cisplatin and carboplatin, are commonly used for treatment of a variety of cancers including bladder, head and neck, lung, gastrointestinal, ovarian, and testicular cancer [6,7].…”